Breast Cancer | Specialty

Anti-PD-L1 Agent MPDL3280A Shows Durable Responses in TNBC

April 20th 2015

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer.

MM-302 Shows Clinical Activity, Tolerability in Heavily-Pretreated HER2+ Breast Cancer

April 20th 2015

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

Dr. Roy Weiner on the Importance of Diversity in Cancer Research

April 17th 2015

Roy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.

Palbociclib Delays Breast Cancer Progression in Phase III Trial

April 15th 2015

The PALOMA-3 trial examining a palbociclib regimen in HR+/HER2- breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival.

BET Bromodomain Inhibitors May Prevent Treatment Resistance in HER2-Positive Breast Cancer

April 14th 2015

Gary L. Johnson, PhD, discusses how BET bromodomain inhibitors could offer a potential solution to lapatinib resistance in patients with HER2-postive breast cancer.

Dr. Irwin on Exercise and Weight Loss After Breast Cancer Diagnosis

April 6th 2015

Melinda L. Irwin, PhD, MPH, associate professor, Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the results of a study she conducted examining the effects of exercise and weight loss in patients with breast cancer.

Future AACR President Discusses Her Leadership Goals and Research Experience

April 3rd 2015

In an interview with OncLive, Nancy E. Davidson discusses her leadership plans for the AACR, as well as precision medicine in oncology®, challenges with research funding, and the role of epigenetics in breast cancer.

Dr. Hudis on Approaching the Topic of Obesity in Cancer

April 2nd 2015

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the challenges with approaching the topic of obesity in patients with cancer.

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

March 27th 2015

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Baylor Sammons Cancer Center Provides Patient-Centered Care

March 26th 2015

BEACON Trial Results, Diet, Obesity, and More

March 26th 2015

Hope Rises for Immunotherapy in Breast Cancer

March 25th 2015

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.

Dr. Sledge on Using PCR To Determine Therapy Benefit for Breast Cancer

March 24th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine discusses the benefits of using pathological complete response rate (PCR) to understand therapy benefit in breast cancer.

Pegram Discusses Optimal Pertuzumab Use in HER2-Positive Breast Cancer

March 24th 2015

In an interview with OncLive, Mark D. Pegram, MD, discusses what available data suggest is the optimal use of pertuzumab for the management of HER2-positive breast cancer.

Evolving Role of Lymph Node Biopsies After Neoadjuvant Therapy for Breast Cancer

March 23rd 2015

OncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.

Lapatinib Falls Short Versus Trastuzumab, Adding Clarity to Frontline HER2-Positive MBC Strategy

March 20th 2015

First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.

BEACON Breast Cancer Study Falls Short, Focus Shifts to Subgroups With Brain or Liver Mets

March 19th 2015

In the phase III BEACON trial, etirinotecan pegol missed the primary endpoint of significantly extending overall survival versus physician's choice of therapy.

How to Involve Community Oncologists in Molecular-Based Research-and Expedite Results

March 13th 2015

What if a negative study had been made available through a secure online registry where patients could sign up, with the assistance of their own oncologists?

Hopkins Researcher Describes Evolving Challenges of Targeting PI3K in Breast Cancer

March 12th 2015

Josh D. Lauring, MD, PhD, of Johns Hopkins Medicine, discusses efforts to develop breast cancer therapies by targeting the PI3K pathway.

Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast Cancer

March 11th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses optimizing neoadjuvant treatments for HER2-positive breast cancer.